BR9808562A - Isolated polynucleotide, host cell, protein, oligonucleotide, antibody, processes to produce a protein encoded by the polynucleotide, to determine a polynucleotide that encodes a beta-amyloid peptide-binding protein (bbp) in a sample, to detect in a sample a polypeptide , to diagnose a disease comprising the aberrant expression of human beta-amyloid peptide (bap), to diagnose, to identify compounds that regulate the activity of a beta-amyloid peptide-binding protein and to treat a patient needing to inhibit the accumulation of beta-amyloid peptide in the brain, and, transgenic or chimeric animal. - Google Patents

Isolated polynucleotide, host cell, protein, oligonucleotide, antibody, processes to produce a protein encoded by the polynucleotide, to determine a polynucleotide that encodes a beta-amyloid peptide-binding protein (bbp) in a sample, to detect in a sample a polypeptide , to diagnose a disease comprising the aberrant expression of human beta-amyloid peptide (bap), to diagnose, to identify compounds that regulate the activity of a beta-amyloid peptide-binding protein and to treat a patient needing to inhibit the accumulation of beta-amyloid peptide in the brain, and, transgenic or chimeric animal.

Info

Publication number
BR9808562A
BR9808562A BR9808562-0A BR9808562A BR9808562A BR 9808562 A BR9808562 A BR 9808562A BR 9808562 A BR9808562 A BR 9808562A BR 9808562 A BR9808562 A BR 9808562A
Authority
BR
Brazil
Prior art keywords
beta
amyloid peptide
protein
polynucleotide
diagnose
Prior art date
Application number
BR9808562-0A
Other languages
Portuguese (pt)
Inventor
Bradley Alton Ozenberger
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9808562A publication Critical patent/BR9808562A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"POLINUCLEOTìDEO ISOLADO, CéLULA HOSPEDEIRA, PROTEìNA, OLIGONUCLEOTìDEO, ANTICORPO, PROCESSOS PARA PRODUZIR UMA PROTEìNA CODIFICADA PELO POLINUCLEOTìDEO, PARA DETERMINAR UM POLINUCLEOTìDEO QUE CODIFICA UMA PROTEìNA DE LIGAçãO A PEPTìDEO BETA-AMILóIDE (BBP) EM UMA AMOSTRA, PARA DETECTAR EM UMA AMOSTRA UM POLIPEPTìDEO, PARA DIAGNOSTICAR UMA DOENçA COMPREENDENDO A EXPRESSãO ABERRANTE DE PEPTìDEO BETA-AMILóIDE HUMANO (BAP), DE DIAGNóSTICO, PARA IDENTIFICAR COMPOSTOS QUE REGULAM A ATIVIDADE DE UMA PROTEìNA DE LIGAçãO A PEPTìDEO BETA-AMILóIDE E PARA O TRATAMENTO DE UM PACIENTE TENDO NECESSIDADE DE INIBIR O ACúMULO DE PEPTìDEO BETA-AMILóIDE NO CéREBRO, E, ANIMAL TRANSGêNICO OU QUIMéRICO". Proporcionam-se novas proteínas que ligam o peptídeo <225>-amilóide humano, polinucleotídeos que codificam estas proteínas, e processos para produzir estas proteínas. Proporcionam-se também processos diagnósticos, terapêuticos e de avaliação, que empregam os polinucleotídeos e polipeptídeos da presente invenção."ISOLATED POLYNUCLEOTYDE, HOST, CELL, PROTEIN, OLIGONUCLEOTYDE, ANTIBODY, PROCESSES TO PRODUCE A PROTEIN ENCODED BY POLYNUCLEOTID, TO DETERMINE A POLYNUCLEOTIDE AMETHING A PROTEIN EMITERATOR, EMPTY ATEATTIC EMITERATOR POLYPEPTIDE, TO DIAGNOSE A DISEASE UNDERSTANDING THE OPENING EXPRESSION OF HUMAN BETA-AMYLOID PEPTIDE (BAP), OF DIAGNOSIS, TO IDENTIFY COMPOUNDS THAT REGULATE THE ACTIVITY OF A PEACEFUL BINDING PROTEIN FOR TEPTENTION TREATMENT INHIBIT THE ACCUMULATION OF BETA-AMYLOID PEPTIDE IN THE BRAIN, AND, TRANSGENIC OR CHIMERIC ANIMAL ". New proteins are provided that bind the human β-amyloid peptide, polynucleotides that encode these proteins, and processes for producing these proteins. Diagnostic, therapeutic and evaluation processes are also provided, which employ the polynucleotides and polypeptides of the present invention.

BR9808562-0A 1997-04-16 1998-04-14 Isolated polynucleotide, host cell, protein, oligonucleotide, antibody, processes to produce a protein encoded by the polynucleotide, to determine a polynucleotide that encodes a beta-amyloid peptide-binding protein (bbp) in a sample, to detect in a sample a polypeptide , to diagnose a disease comprising the aberrant expression of human beta-amyloid peptide (bap), to diagnose, to identify compounds that regulate the activity of a beta-amyloid peptide-binding protein and to treat a patient needing to inhibit the accumulation of beta-amyloid peptide in the brain, and, transgenic or chimeric animal. BR9808562A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6458397P 1997-04-16 1997-04-16
PCT/US1998/007462 WO1998046636A2 (en) 1997-04-16 1998-04-14 β-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME

Publications (1)

Publication Number Publication Date
BR9808562A true BR9808562A (en) 2000-05-23

Family

ID=22056941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808562-0A BR9808562A (en) 1997-04-16 1998-04-14 Isolated polynucleotide, host cell, protein, oligonucleotide, antibody, processes to produce a protein encoded by the polynucleotide, to determine a polynucleotide that encodes a beta-amyloid peptide-binding protein (bbp) in a sample, to detect in a sample a polypeptide , to diagnose a disease comprising the aberrant expression of human beta-amyloid peptide (bap), to diagnose, to identify compounds that regulate the activity of a beta-amyloid peptide-binding protein and to treat a patient needing to inhibit the accumulation of beta-amyloid peptide in the brain, and, transgenic or chimeric animal.

Country Status (18)

Country Link
EP (1) EP0975753A2 (en)
JP (3) JP2001523093A (en)
KR (1) KR20010006393A (en)
CN (2) CN1690203A (en)
AU (1) AU740445B2 (en)
BR (1) BR9808562A (en)
CA (1) CA2286484A1 (en)
EA (1) EA004256B1 (en)
EE (1) EE9900482A (en)
GE (1) GEP20043386B (en)
HU (1) HUP0003116A3 (en)
ID (1) ID24914A (en)
IL (3) IL132236A0 (en)
NO (1) NO995062L (en)
NZ (1) NZ500216A (en)
SK (1) SK143299A3 (en)
UA (1) UA72875C2 (en)
WO (1) WO1998046636A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US7005295B1 (en) 1997-04-16 2006-02-28 Wyeth β-amyloid peptide-binding proteins and polynucleotides encoding the same
CA2346008A1 (en) * 1998-10-13 2000-04-20 American Home Products Corporation G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same
US6455082B1 (en) * 1999-04-26 2002-09-24 Nestec S.A. Shelf-stable calcium fortified milk and dairy products
WO2001029225A1 (en) * 1999-10-21 2001-04-26 Panorama Research, Inc. A general method for optimizing the expression of heterologous proteins
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
CN103189050B (en) 2010-10-26 2017-09-29 Ac免疫有限公司 The construct based on liposome comprising the peptide modified by hydrophobic part
CN102060912B (en) * 2010-11-22 2012-11-14 清华大学 Amyloid protein oligomer conformation type epitope polypeptide and application thereof
CN111320678B (en) * 2020-03-09 2023-06-09 安亭生物有限责任公司 Antibacterial peptide mutant and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0332640A1 (en) * 1986-11-17 1989-09-20 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
IL115743A0 (en) * 1994-10-28 1996-01-19 American Nat Red Cross A mammal with cells containing a transgene and its production
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide

Also Published As

Publication number Publication date
SK143299A3 (en) 2000-09-12
CN1268973A (en) 2000-10-04
AU740445B2 (en) 2001-11-01
WO1998046636A2 (en) 1998-10-22
JP2001523093A (en) 2001-11-20
IL132236A0 (en) 2001-03-19
GEP20043386B (en) 2004-02-10
NO995062L (en) 1999-12-14
KR20010006393A (en) 2001-01-26
HUP0003116A2 (en) 2001-01-29
IL132236A (en) 2007-03-08
JP2008253275A (en) 2008-10-23
EP0975753A2 (en) 2000-02-02
CN1690203A (en) 2005-11-02
ID24914A (en) 2000-08-31
UA72875C2 (en) 2005-05-16
NZ500216A (en) 2001-06-29
EA199900941A1 (en) 2000-06-26
IL179047A0 (en) 2007-03-08
EA004256B1 (en) 2004-02-26
CA2286484A1 (en) 1998-10-22
HUP0003116A3 (en) 2003-03-28
NO995062D0 (en) 1999-10-15
EE9900482A (en) 2000-06-15
WO1998046636A3 (en) 1999-01-28
CN1196785C (en) 2005-04-13
JP2008104465A (en) 2008-05-08
AU7115698A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
Segal et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.
Götz et al. Neurotrophin-6 is a new member of the nerve growth factor family
JP2783407B2 (en) Precursor protein of APC polypeptide, DNA specifying this genetic information, and diagnostic use of DNA and said protein
BR9808562A (en) Isolated polynucleotide, host cell, protein, oligonucleotide, antibody, processes to produce a protein encoded by the polynucleotide, to determine a polynucleotide that encodes a beta-amyloid peptide-binding protein (bbp) in a sample, to detect in a sample a polypeptide , to diagnose a disease comprising the aberrant expression of human beta-amyloid peptide (bap), to diagnose, to identify compounds that regulate the activity of a beta-amyloid peptide-binding protein and to treat a patient needing to inhibit the accumulation of beta-amyloid peptide in the brain, and, transgenic or chimeric animal.
Jarskog et al. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia
PT1349870E (en) Compositions for the therapy and diagnosis of ovarian cancer
Mouton et al. The periaqueductal gray in the cat projects to lamina VIII and the medial part of lamina VII throughout the length of the spinal cord
Andrade et al. Effect of electrolytic and neurotoxic lesions of the median raphe nucleus on anxiety and stress
WO2001066595A3 (en) Human fgf-23 gene and gene expression products
CN107913395B (en) Use of polypeptides associated with neuronal excitatory injury for preventing, alleviating or treating pain
BR0309638A (en) Polypeptide, purified nucleic acid molecule, vector, host cell, ligand, compound, method of diagnosing a disease in a patient, use of a polypeptide, pharmaceutical composition, vaccine composition, methods of treating a disease in a patient, monitoring therapeutic treatment of disease in a patient, and identifying a compound that is effective in the treatment and / or diagnosis of disease, kit, knockout or transgenic non-human animal, and method for selecting an effective compound for disease treatment
WO2001066596A3 (en) Human fgf-23 gene and gene expression products
Lovick Analgesia and the cardiovascular changes evoked by stimulating neurones in the ventrolateral medulla in rats
EP0804564A1 (en) Neural axon outgrowth modulators
HÄRTNER et al. Fast and slow isoforms of troponin I and troponin C: distribution in normal rabbit muscles and effects of chronic stimulation
BR0215284A (en) Polypeptide, fragment or functional equivalent, purified nucleic acid molecule, vector, host cell, ligand, compound, method for diagnosing a disease in a patient, use of a polypeptide, pharmaceutical composition, vaccine composition, method for treating a disease in a patient, method for monitoring therapeutic treatment of disease in a patient, method for identifying a compound, kit, transgenic or inactivating non-human animal, and method for screening an effective compound for treating disease
Martins et al. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion
CU23412A3 (en) DIAGNOSIS AND TREATMENT OF DISEASES USING ANTI-ANTI-RECEIVING ANTIBODIES OF VBETA CELLS OR PEPTIDES THAT ARE RECOGNIZED BY SUCH ANTIBODIES, AND REGULATING PROTEIN OF THE ENDOCRINE SECRETION 1 (PRSE1)
RU2001130755A (en) DIAGNOSIS OF THE RISK OF DEVELOPMENT IN A SUBJECT OF ATHEROSCLEROSIS OR DIABETIC RETINOPATHY
BRPI0409802A (en) method for identifying a member of the secfam3 family, polypeptide, purified nucleic acid molecule, vector, host cell, ligand, compound, method for diagnosing a disease in a patient, use of a polypeptide, pharmaceutical composition, vaccine composition, methods for treating a disease in a patient, to monitor the therapeutic treatment of disease in a patient, and to identify a compound that is effective in treating and / or diagnosing the disease, kit, transgenic or muted nonhuman animal, and method for screening for an effective compound to treat disease
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
WO2005052123A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor variant of the relaxin receptor, hgprbmy5v1, and variants thereof
MXPA03005500A (en) A novel human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1.

Legal Events

Date Code Title Description
TC Change of name
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO COM BASE O ARTIGO 8O COMBINADO AO ART. 13 E ARTS. 10 (IX), 18 (III), 24 E 25 DA LEI 9.279/96.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.